West Pharmaceutical
778 hedge funds and large institutions have $27B invested in West Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 97 funds opening new positions, 291 increasing their positions, 265 reducing their positions, and 92 closing their positions.
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
11% more capital invested
Capital invested by funds: $24.3B → $27B (+$2.73B)
10% more repeat investments, than reductions
Existing positions increased: 291 | Existing positions reduced: 265
5% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 92
0.03% more ownership
Funds ownership: 93.59% → 93.62% (+0.03%)
1% less funds holding
Funds holding: 783 → 778 (-5)
25% less call options, than puts
Call options by funds: $124M | Put options by funds: $167M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$181M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$136M |
| 3 |
Holocene Advisors
New York
|
+$132M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$116M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$82.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$222M |
| 2 |
Morgan Stanley
New York
|
-$132M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$119M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$109M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$102M |
WST Hedge Fund Activity: Q1 2024 in Review
778 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2024, worth a combined $27B — up 11% from $24.3B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new WST positions and 92 closed out — a net gain of 5 holders — while 291 added to existing stakes and 265 trimmed.
The largest buyer was Millennium Management, adding an estimated $181M. The largest seller was Neuberger Berman Group, cutting an estimated $222M.
- 778 institutional investors held West Pharmaceutical (WST) as of Q1 2024, down from 783 in Q4 2023.
- Funds reported $27B of West Pharmaceutical stock for Q1 2024, up 11% quarter-over-quarter.
- 97 funds opened new West Pharmaceutical positions in Q1 2024 and 92 closed out, a net change of +5 holders.
- The largest West Pharmaceutical buyer in Q1 2024 was Millennium Management, an estimated $181M added.
- The largest West Pharmaceutical seller in Q1 2024 was Neuberger Berman Group, an estimated $222M sold.
Based on aggregated 13F filings for Q1 2024.